Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients - Wikidata - awgldk - TriplyDB

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients

http://www.wikidata.org/entity/Q28748971

about

sameAs

CCR5 antagonism in HIV infection: current concepts and future opportunities A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1 Inflammation, Immune Activation, and Antiretroviral Therapy in HIV Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-a Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease.Effect of maraviroc on HIV disease progression-related biomarkers.Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.Transient expansion of activated CD8(+) T cells characterizes tuberculosis-associated immune reconstitution inflammatory syndrome in patients with HIV: a case control study.The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection.Drug combinations for HIV: what's new?Drug safety evaluation of maraviroc for the treatment of HIV infection.Tuberculosis-immune reconstitution inflammatory syndrome in HIV: from pathogenesis to prediction.Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients.A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study.Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers.Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.Off-label use of maraviroc in clinical practice.Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.

P2860

Q26865457-8193BD5A-683F-4724-BD44-660D70763FF4 Q27344720-D2E7F1A3-5934-40FD-AEF6-85B60082C375 Q28552729-98795763-3E67-443B-9181-ECB8D8C471FF Q28728667-C7C88B3F-F8CA-4DEC-91AD-E5BB7DAA95D6 Q28741704-AFC29655-548A-4232-8CC6-229FF3A66679 Q33649200-B1479581-F6B1-421D-A5B7-C7D4E2630CC4 Q33725916-ED22079C-0527-4E2C-8E79-48D820562EFC Q33912595-7032892B-E9DA-4C8E-B0E7-7C6010FD5055 Q34400849-F13F4A4A-312C-445B-8D77-88CEFE3F08A3 Q34718135-B7F0F787-AD57-4336-BC74-ACA8207241C4 Q35109483-77C8B9E9-D063-4BD6-AFEC-1BE5C04DC8D7 Q35656939-816A56EC-3D4D-4DB0-8744-F558A06D85D6 Q36030485-0C037E25-FF70-4FE6-927C-6CA0663309D0 Q36263361-6D468706-EF64-49D0-9B85-AB584D7F39E5 Q36279270-217C9212-CFC5-4355-9693-7E9975F733B3 Q36364075-71D23E16-51C8-42EF-8A1D-78ACABF0C280 Q36509593-396C28E2-1ED5-4917-80D6-E0A1D9BFC7D7 Q36921904-8E0FEFC5-1F38-4E41-B848-F2C31A7E3B86 Q36938539-B875D9FF-8799-4E4F-99C2-32B6E37DA6C7 Q37034835-E7CDD582-77A0-4114-9D63-D4B7EAB5E9D1 Q37098066-859A4B10-9111-4752-8D16-52BC989EDDD7 Q37250180-DA8A1BA6-DE82-437A-93E3-2AC5FBB1C515 Q37521828-51F8CAE9-04E0-465A-96D8-A3DB7A8FAA79 Q37862747-7B2B8608-D0FF-4D80-94F9-9C607DA347FF Q37949638-F97851E5-B043-4EC2-9A15-1333667382FF Q37961188-488343E3-1DFD-4E0B-9D31-EF4537AE2F1C Q38192061-92E479D4-7665-44C3-9284-A0A5D5E514AE Q38603237-B495E18A-99FD-4380-9455-8A98C6CB054B Q38702121-E5136708-C157-4557-8093-170178F169EC Q39230042-6FD8C785-BBDD-407C-8122-20E02DCA5187 Q39563189-800ECEEF-8594-4CEB-92F6-07AE20584A76 Q39696831-1AFDFA98-8770-408F-8012-82D580196D81 Q40633578-0B40FF43-8535-4E9B-97BF-00069DC254CC Q41024442-194F2463-CC69-48A8-A338-13193E98FA6F Q41257300-784B212C-94F4-4C70-9B93-4253EDEC27FF Q41989387-E0945151-AE82-45CE-8F1A-0AC15705E275 Q42219111-422D7B44-B80C-4704-9341-57789E877B08 Q42222937-51777FF7-E609-496B-A927-591404B55BC1 Q42654565-515F3820-4B87-413E-A3FB-54E350195B21 Q44115326-5A9875C9-31CE-40AF-B49F-8BCE0A533550

P2860

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients

http://www.wikidata.org/entity/Q28748971

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@ast

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@en

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@nl

type

label

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@ast

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@en

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@nl

prefLabel

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@ast

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@en

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@nl

P1433

Q28748971-696C5FF2-FF2A-45AD-96ED-51DFC01B3ECD

P1476

Q28748971-57D707C6-F724-40D0-91E7-709C539CEA6F

P2093

Q28748971-166365D0-53FE-4830-8E72-115849B01DBC

Q28748971-30AF528B-2CB4-4227-AFB2-0D3066FAD617

Q28748971-326EED5F-B308-4857-8835-B60ADC38579D

Q28748971-3434BF35-FD78-48F7-8F9B-BE6EFE38883D

Q28748971-7E4CA087-D764-4282-B242-18068110BE02

Q28748971-8C242168-3EE6-42EA-9BE7-671D7488823D

Q28748971-D2A68EE1-4500-4CFB-B7E8-BEF8C394AA59

Q28748971-D5A29D1E-FC9F-42C7-AE7A-2AF1C461CD72

P2860

Q28748971-1FF9F5F6-0BA6-4278-8FC6-EF9B5075B402

Q28748971-26F9FE62-E777-4A1B-A2B1-76D8DC467FC6

Q28748971-28EBED05-4D34-4DA4-8305-D22206E671D2

Q28748971-617FCB6A-D517-45CA-901D-09FEF3A74EB4

Q28748971-6DA9B4CC-08F8-452B-94F3-E52B9E937395

Q28748971-82829D75-7659-41B2-BC01-2E94C8026EDE

Q28748971-9D7A1B6D-B78D-41CB-8E5C-93FE62B2EB39

Q28748971-9E618C7C-9C1E-4983-8445-8A9E64259E0E

Q28748971-ADD8DACB-2C30-496B-8007-2EB487FC0B0C

Q28748971-B3D80A3B-1883-4122-ACA6-C22818BCB5FA

P304

Q28748971-CBB2E074-FDA0-4215-940A-DA68C7E77FD8

P31

Q28748971-66A80CED-023E-42C1-9452-9589275DC4B6

P3181

Q28748971-343ECC98-24B6-4D61-BE05-C048D2FF8D35

P356

Q28748971-81F7FF3C-D5F7-4811-B15D-4181F648D91F

P407

Q28748971-4C172183-D172-49A2-8B4B-2A19563EB6BF

P433

Q28748971-23E00D94-0D90-42FA-B43E-F338E5FD50F5

P478

Q28748971-3C40EB1B-9843-4447-B2FE-25B20D247F52

P50

Q28748971-AB160FDF-BF31-4C27-9793-9E5A47952D2F

P577

Q28748971-3516113A-76E3-4E0E-8307-4C508CA48112

P5875

Q28748971-8B05FBA3-0429-410C-B2E7-5DF0177B0640

P698

Q28748971-3B0F217B-B4A1-418F-BF37-99DDEF7FA0AC

P921

Q28748971-1604BBFE-080D-4549-8C46-98701DCA9AE0

Q28748971-827B023F-3386-44F7-9251-57BD4EE103F2

P932

Q28748971-CCFF08E6-C18C-477B-94E3-DE39121EDA6D

P3181

P356

JOURNAL.PONE.0013188

P1433

P1476

Effects of maraviroc and efavi ...... rises in HIV-infected patients

@en

P2093

Hernan Valdez

http://www.w3.org/2001/XMLSchema#string

Howard Mayer

http://www.w3.org/2001/XMLSchema#string

James Eason

http://www.w3.org/2001/XMLSchema#string

James Goodrich

http://www.w3.org/2001/XMLSchema#string

Jayvant Heera

http://www.w3.org/2001/XMLSchema#string

Magdalena Kalinowska

http://www.w3.org/2001/XMLSchema#string

Michael M Lederman

http://www.w3.org/2001/XMLSchema#string

Natasa Rajicic

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Viral and host factors in the pathogenesis of HIV infection.

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

CCR5 deletion protects against inflammation-associated mortality in dialysis patients.

Association of C-reactive protein and HIV infection with acute myocardial infarction.

Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.

P304

e13188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

398644

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0013188

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas Funderburg

P577

2010-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47430621

http://www.w3.org/2001/XMLSchema#string

P698

20949133

http://www.w3.org/2001/XMLSchema#string

P921

P932

2950842

http://www.w3.org/2001/XMLSchema#string